Document is current
Any future updates will be listed below
-
Authors
Burton, Mark A.
Garratt, Emma S.
Hewitt, Matthew O.
Sharkh, Hanan Y.
Antoun, Elie
Westbury, Leo D.
Dennison, Elaine M.
Harvey, Nicholas C.
Cooper, Cyrus
MacIsaac, Julia L.
Kobor, Michael S.
Patel, Harnish P.
Godfrey, Keith M.
Lillycrop, Karen A. https://orcid.org/0000-0001-7350-5489
-
Funding
Funding for this research was provided by:
Benevolent AI Ltd
NIHR Southampton Biomedical Research Centre
UK Research and Innovation (BB/W018284/1, BB/W018284/1)
MRC (MC_U47585827, MC_U47585827, MC_U47585827, MC_U47585827, MC_U47585827)
Arthritis Research UK
Royal Osteoporosis Society
International Osteoporosis Foundation
Cohen Trust
NIHR (U24AG047867)
Biotechnology and Biological Sciences Research Council (ES/M0099X)
- License Information
-
More Information
Article History
Received: 11 May 2023
Accepted: 9 October 2023
First Online: 28 October 2023
Declarations
:
: This study received ethical approval from the Hertfordshire Research Ethics Committee (number 07/Q0204/68) and was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments.
: Not applicable.
: K.M. Godfrey and H.P. Patel have received reimbursement for speaking at conferences sponsored by companies selling nutritional products. N.C. Harvey reports personal fees, consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, UCB, Kyowa Kirin, Servier, Shire, Consilient Healthcare and Internis Pharma, outside the submitted work. C. Cooper has received consultancy fees and honoraria from Amgen, Danone, Eli Lilly, GlaxoSmithKline, Medtronic, Merck, Nestlé, Novartis, Pfizer, Roche, Servier, Shire, Takeda, and UCB. M.A. Burton, E.S. Garratt, E. Antoun, K.M. Godfrey, and K.A. Lillycrop are part of academic research programmes that have received research funding from BenevolentAI Bio Ltd., Nestec, and Danone. The other authors declare that they have no conflicts of interest.
